Novel therapies slow CKD progression in patients with diabetes

(ERA-EDTA) The recently published CREDENCE study showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. Canagliflozin was associated with a 34% risk reduction of the renal end point. The SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news